Chemotherapy and immunotherapy of brain tumors: What the epileptologist must know

Authors

  • Lisa R. Rogers

    Corresponding author
    1. Department of Neurology, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio, U.S.A
    • Address correspondence to Lisa R. Rogers, Department of Neurology, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106, U.S.A. E-mail: lisa.rogers1@uhhospitals.org

    Search for more papers by this author

Summary

I present an overview of therapy for the most common brain tumors encountered in clinical practice if adult patients. Current therapy paradigms and evolving therapies are reviewed. The introduction of non–enzyme-inducing antiepileptic drugs (NEIADs) has simplified the approach to combined medical treatment of epilepsy and brain tumors, but the major interactions between enzyme-inducing antiepileptic drugs (EIAEDs) are included, to serve as guidance in selecting these medications if they are required.

Ancillary